GSK heads into Tuesday's Q2 results with one notable shift since the last preview: options positioning has eased from its most defensive levels, even as the stock remains a relative underperformer against the broader pharma pack.
The clearest change is in how options traders are leaning. The put/call ratio has pulled back to 1.28, below its 20-day average of 1.31 — a mild reversal from the more anxious readings of mid-July, when the ratio briefly touched its 52-week high of 1.50. That spike came precisely when GSK's underperformance against peers was sharpest. The pullback now suggests some of that near-term hedging has been unwound heading into the event, though the ratio remains structurally elevated relative to its 52-week low of 0.40, reflecting a market that has consistently favoured puts over calls for GSK throughout 2026.
The lending market continues to offer no signal of meaningful short pressure. Short interest has climbed roughly 51% over the past month in share terms — but availability remains near 200%, meaning there are roughly two shares available to borrow for every one already lent out. Borrowing costs are low at 0.58% and have eased slightly over the past week. The ORTEX short score of 45 is middling, well within normal range. Short sellers building positions are doing so in a relaxed lending environment, not one under stress.
The analyst picture is mixed and somewhat stale. Citigroup reinstated coverage on July 24 with a Neutral rating — the only truly fresh action ahead of the print. Barclays moved to Underweight in January, while Jefferies carries a Buy. The consensus mean price target of $42.74 appears materially outdated given the stock currently trades near $51, and should be treated with caution. What the recent note history does confirm is that GSK's quality fundamentals remain solid — a Piotroski F-score of 8, ROA near 10%, and a dividend score in the 94th percentile — but momentum has been the drag, with the 91-day relative strength deeply negative and the 50-day moving average now barely above the 200-day. Last quarter's print ended with a 4% one-day drop and a 7% five-day decline, the most recent comparable data point available.
The July 28 print will test whether the Q2 vaccine and specialty medicine performance that drove the recent analyst upgrades can repeat — and whether guidance is strong enough to close the gap with peers that have already rerated higher.
See the live data behind this article on ORTEX.
Open GSK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
